Our Leadership

AbGenomics’ senior management is built on a team of individuals possessing strong academic knowledge, high-level managerial experience and scientific expertise in a range of fields including life science, pharmacology, healthcare and immunology.

Ron (R.H.) Lin, Ph.D.

Chief Executive Officer

Dr. Lin is the founder of AbGenomics. He is the key inventor of more than a dozen worldwide patents. Prior to joining AbGenomics, Dr. Lin was Professor and Director of Graduate Institute of Immunology, College of Medicine, National Taiwan University. Dr. Lin also served as an Associate Editor for Journal of Biomedical Science and a member of the Editorial Board for Int. Immunopharmacology. He received his Diplom, Summa Cum Laude, and Doctor (in Immunology), Magna Cum Laude, degrees from the University of Tübingen in Germany. He has conducted his research works in 3 world renowned institutions: Max Planck Institute for Immunogenetics in Germany, Basel Institute for Immunology in Switzerland, and Immunobiology Division at Howard Hughes Medical Institute at Yale University. In his previous academic research journey he has conducted translational researches and published more than 50 refereed papers.

Shih-Yao Lin, MD., Ph.D.

Chief Medical Officer and President of AbG BV

Prior to joining AbGenomics, Dr. Lin was a research fellow (1998-2004) at Laboratory of Allergy and Immunology, Department of Experimental Pathology, in Boston, USA. Dr. Lin received his MD degree from School of Medicine, National Taiwan University, and completed the resident training at the Department of Laboratory Medicine, National Taiwan University Hospital. He also received the PhD degree (Immunology) from Centre d'Immunologie de Marseille-Luminy, University of Aix-Marseille II in Marseille, France.

Joseph S. McCracken, DVM, MS

Head of Business Development

Joe McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives; and serves on the Boards of Alkahest, Inc., EdiGENE Corporation, Kindred Biosciences, Regimmune Inc., and Savara Pharmaceuticals. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. From October 2009 until July 2011 he was General Manager, Roche Pharma Japan & Asia Regional Head, Roche Partnering. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate in Veterinary Medicine from The Ohio State University.

Leewen Lin, Ph.D., LL.M.

Vice President of Administration, AbG BV Taiwan

Prior to AbGenomics, Dr. Lin had been Senior Staff Fellow in Center of Biologics Evaluation and Research, US Food and Drug Administration, Director of Biotechnology Development Program of Yung-Shin Pharmaceutical, and Vice President of BioTrust International Corporation. Dr. Lin had been a member of the Intellectual Property Committee of Academia Sinica, and served as an advisor to the Biotechnology and Pharmaceutical Promotion Group, Ministry of Economic Affairs, Taiwan, on legal and regulatory affairs. Dr. Lin received her Ph.D. in Biochemistry from North Carolina State University, and obtained her postdoctoral training in Genetics and Molecular Biology in Harvard Medical School and Massachusetts General Hospital. In addition, she enrolled in the J.D. program in Georgetown Law School while working full time at FDA. She received her L.L.M at Soochow University Law School, Taipei, Taiwan.

Hazel (T.Y.) Cheng, Ph.D.

Vice President of Clinical and CMC Project Management

With more than 20 years experiences in biotech and pharma industries, Dr. Cheng expertizes in investigational new drug enabling program, and drug development, strategic sourcing, project management and clinical operation. Prior to joining AbGenomics, she was Vice President of Science and Technology at Westar Nutrition Corp., Costa Mesa in California where she led the research development team, oversee the logistics of manufacture operation and ensure the pharmaceutical cGMP and regulatory compliance. Dr. Cheng received her Ph.D. in Immunology from National Taiwan University School of Medicine.

Hsiao-Wen Tuan, MBA

Associate Vice President of Finance

Prior to joining AbGenomics, Mr. Tuan held senior management positions in companies of Asialoc Corporation, Shye Shyang Mechanical Industrial Co., Ltd., and Yuanta Securities. Tuan is an expert in financial planning with considerable experience, including doing financial planning in China. He received his B.B.A. in money and banking from National Chengchi University, M.B.A in finance from Tamkang University.

Crystal Lin

Controller

Crystal Lin, joined AbGenomics since 2008, currently serves as a Controller and oversees all accounting and tax compliance matters of all AbGenomics Group companies. Prior to joining AbGenomics, Crystal had gained her professional experience in accounting and auditing while working at PricewaterhouseCoopers in Taiwan and she was the primary in-charge, responsible for leading audit team to completing financial statement audit and tax returns for many publicly traded and listed companies, including Mega Bank and DeBeers Group etc.. Crystal received her B.B.A. in both Accounting and Finance from Simon Fraser University in B.C. Canada.

Patrick Y. Yang, Ph.D.

(Executive Chairman of the Board, Audit Committee Member, Compensation Committee Member)

Dr. Pat Yang is Executive Chairman, AbGenomics. In addition to serving on corporate boards, he also works as an independent consultant in the Biopharmaceutical industry.
Most recently, Dr. Yang worked at Juno Therapeutics in Seattleas Executive Vice President from September 2017 to January 2019.
Previously, Dr. Yang was Roche’s Global Head of Technical Operations in Switzerland from 2009 to 2013. In this role, he was responsible for Roche’s biopharmaceutical process development, engineering, quality, technical regulatory, supply chain and 21 manufacturing plants with approximately 15,000 employees around the world -- with an operating budget of $4.5 billion per year. He was previously executive vice president, Product Operations of Genentech, Inc. based in the San Francisco Bay area. Dr. Yang joined Genentech in 2003 as vice president, Manufacturing and Engineering, and was promoted to senior vice president, Product Operations, in December 2004, then to executive vice president in January 2006.
Prior to joining Genentech, Dr. Yang served for 11 years at Merck & Company in New Jersey in various leadership positions including vice president of Asia Pacific Operations and vice president of Global Supply Chain Management. Prior to joining Merck in 1992, Yang spent 12 years at General Electric, serving in several research, engineering, technology, and manufacturing leadership roles with increasing scope of responsibilities. Before GE, Dr. Yang spent five years in aerospace control systems research and development with Life Systems, Inc.
Dr. Yang holds a Bachelor of Science from the National Chiao Tung University in Taiwan, a Master of Science from the University of Cincinnati, and a doctorate in engineering from Ohio State University, Columbus, Ohio. Dr. Yang is a member of Board of Directors for three public companies: Codexis, Amyris, and PharmaEssentia. He also serves on the corporate boards of several private companies including Acepodia, Archigen Biotech, Sana Biotech, and Taiwania Capital Management. He previously served on the boards of two other public companies: Tesoro/Andeaver (2010-2018) and Celladon (2014-2016).

Nai-Yu Pai, CPA

(Chairman of Audit Committee, Compensation Committee Member)

Mr. Nai-Yu Pai, the founder of Pai Accountancy LLP, is a Certified Public Accountant who holds a master’s degree in Accounting from Saint John’s University in New York, where his primary area of emphasis was in taxation and auditing. He also holds another master’s degree in Taxation from Golden Gate University. Mr. Pai has over 40 years of accounting and auditing experience.
Mr. Nai-Yu Pai has founded two companies – Authenex Inc. and F2 Ware Inc. – and served as CEO and Board member of both companies. Mr. Pai also serves as Board of Director for a few private companies including Sigrity Inc.; Vivente, Inc.; Gaia Interactive Inc.; Deep Vision; ProGrade; and Chinese Cancer Memorial Foundation (a 501c(3) company). Mr. Pai previously served as a Board of Director and the Chairman of the Audit Committee of JA Solar (listed on NASDAQ), and as a Board of Director and a member of the audit committee of AXT (Listed on NASDAQ). Mr. Pai has assisted over 20 companies in fundraising and merger and acquisition activities, including Marvell Semiconductor (listed on NASDAQ); Silicon Motion (listed on NASDAQ); @Road; Accton (listed on Taiwan stock market); AMlogic (listed on Shanghai technology board); and Hot rail.
Mr. Pai has also been actively involved in the community. He had acted as the CFO and Board of Director of the Chinese Cancer Memorial Foundation (CCMF). CCMF has hosted events that have raised over a million dollars in donations to assist over 3,000 cancer patients and their families in Silicon Valley. He was also previously a host of the Tax Talk Show on KPST Channel 66 in San Francisco, where he discussed complex tax laws to viewers.

STEPHEN G. JUELSGAARD, D.V.M., J.D.

(Chairman of Compensation Committee, Audit Committee Member)

Stephen (“Steve”) Juelsgaard, is a former executive vice president, secretary and chief compliance officer of Genentech, Inc. He reported to Genentech’s CEO and was responsible for Genentech’s Corporate Law, Intellectual Property, Government Affairs (Federal and State), Human Resources, and Healthcare Compliance groups, as well as the Business Services group, which included Strategic Facilities Planning, Corporate Security, Business Continuity, and Environment, Health & Safety. He also chaired Genentech’s Capital Governance Committee, which oversaw major capital expenditures at the company and was a member of Genentech’s Executive Committee, the most senior management committee at the company. He served as secretary to Genentech’s Board of Directors and each of the Board’s Committees from 1997 to 2009. Dr. Juelsgaard’s career at Genentech spanned 24 years. He joined Genentech in 1985 as corporate counsel and became senior corporate counsel in 1989. In 1992 he became vice president, Corporate Law and in 1994 was named general counsel, a role he served in through 2007. He was named a senior vice president in 1998. In 2002, he was appointed executive vice president and in 2005 was named chief compliance officer. He was the company’s representative on the board of directors of the California Healthcare Institute from 2005 until 2009. He left Genentech in 2009 when it became a wholly owned subsidiary of Roche. Prior to joining Genentech, he was an associate for three years with the law firm Wilson Sonsini Goodrich & Rosati in Palo Alto, California. Prior to attending law school, he was engaged for three years in a private veterinary medical (equine) practice in Southern California. He is a member of the Independent Citizens Oversight Committee (board of directors) of the California Institute for Regenerative Medicine where he also is the chairman of the ICOC’s Intellectual Property and Industry Subcommittee and serves on the Application Review, Science Finance and Evaluation Subcommittees. He is a past member of the board of directors of Ivivi Health Sciences LLC, a private medical device company, and of Rio Grande Neurosciences, Inc., a private company engaged in the development of pulsed electromagnetic field technology as well as transcranial electrical stimulation and transcranial magnetic stimulation technologies. Dr. Juelsgaard received his Doctor of Veterinary Medicine degree from Iowa State University in 1972 and a Masters degree in Veterinary Clinical Sciences in 1975 from Iowa State University where his research was focused on immunology. In 1982 he received a law degree from Stanford Law School.

Sean P. Bohen, M.D., Ph.D.

Dr. Sean Bohen was executive vice president of global medicines development and chief medical officer at AstraZeneca from 2015 to 2019. He was responsible for AstraZeneca’s worldwide product development and clinical programs to address unmet medical needs and renew AstraZeneca's product pipeline. Prior to joining AstraZeneca, he was Senior Vice President of Genentech Early Development from January, 2011. Dr. Bohen’s career at Genentech spanned 12 years. He joined Genentech in 2003 as Assistant Medical Director, Rituxan Heme/Onc. He was Associate Medical Director of Oncology Exploratory Clinical Development in 2004 and became Medical Director in 2005, then Associate Director in April, 2006. In October, 2006, he was Director of ITGR Exploratory Clinical Development and was promoted to Senior Director in October, 2007, then to Vice President of Immunology Development in August, 2008. In addition, Dr. Bohen also was an Adjunct Clinical Instructor in Oncology at Stanford University School of Medicine from 2002 to 2011. He received his Bachelor of Science (Bacteriology) from University of Wisconsin-Madison, and M.D. and Ph.D. in Biochemistry from University of California, San Francisco.

Yung-Hua Chung

Mr. Chung started leading EuroKing Co., Ltd. as the Chairman and President since 1993. Aside from this Chairman position, he is also the Board Director for Well-Being Biochemical Corp. and Board Director of AbGenomics Corp., Ltd.
His earlier career was in Collins Co. as a Manager.

Oak Grove Investments Group Limited

A company focused on new drug development was established in the British Virgin Islands in December 2012.

Ron (R.H.) Lin, Ph.D.

Dr. Lin is the founder of AbGenomics. He is the key inventor of more than a dozen worldwide patents. Prior to joining AbGenomics, Dr. Lin was Professor and Director of Graduate Institute of Immunology, College of Medicine, National Taiwan University. Dr. Lin also served as an Associate Editor for Journal of Biomedical Science and a member of the Editorial Board for Int. Immunopharmacology. He received his Diplom, Summa Cum Laude, and Doctor (in Immunology), Magna Cum Laude, degrees from the University of Tübingen in Germany. He has conducted his research works in 3 world renowned institutions: Max Planck Institute for Immunogenetics in Germany, Basel Institute for Immunology in Switzerland, and Immunobiology Division at Howard Hughes Medical Institute at Yale University. In his previous academic research journey he has conducted translational researches and published more than 50 refereed papers.